IL104620A - Humanized monoclonal antibodies against human interleukin-5 - Google Patents

Humanized monoclonal antibodies against human interleukin-5

Info

Publication number
IL104620A
IL104620A IL10462093A IL10462093A IL104620A IL 104620 A IL104620 A IL 104620A IL 10462093 A IL10462093 A IL 10462093A IL 10462093 A IL10462093 A IL 10462093A IL 104620 A IL104620 A IL 104620A
Authority
IL
Israel
Prior art keywords
monoclonal antibodies
antibodies against
against human
humanized monoclonal
human interleukin
Prior art date
Application number
IL10462093A
Other languages
English (en)
Other versions
IL104620A0 (en
Original Assignee
Schering Plough Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Plough Corp filed Critical Schering Plough Corp
Publication of IL104620A0 publication Critical patent/IL104620A0/xx
Publication of IL104620A publication Critical patent/IL104620A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL10462093A 1992-02-06 1993-02-04 Humanized monoclonal antibodies against human interleukin-5 IL104620A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83284292A 1992-02-06 1992-02-06

Publications (2)

Publication Number Publication Date
IL104620A0 IL104620A0 (en) 1993-06-10
IL104620A true IL104620A (en) 2000-02-29

Family

ID=25262763

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10462093A IL104620A (en) 1992-02-06 1993-02-04 Humanized monoclonal antibodies against human interleukin-5

Country Status (21)

Country Link
US (1) US6451982B1 (enExample)
EP (1) EP0625201A1 (enExample)
JP (2) JPH07505767A (enExample)
KR (2) KR0150060B1 (enExample)
CN (1) CN1077991A (enExample)
AR (1) AR248044A1 (enExample)
AU (1) AU683836B2 (enExample)
CA (1) CA2129445A1 (enExample)
CZ (1) CZ291039B6 (enExample)
FI (1) FI943635L (enExample)
HU (1) HUT67943A (enExample)
IL (1) IL104620A (enExample)
NO (1) NO942912L (enExample)
NZ (1) NZ249633A (enExample)
PL (1) PL176393B1 (enExample)
RU (1) RU94045919A (enExample)
SG (1) SG49597A1 (enExample)
SK (1) SK280610B6 (enExample)
TN (1) TNSN93012A1 (enExample)
WO (1) WO1993016184A1 (enExample)
ZA (1) ZA93779B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA93779B (en) 1992-02-06 1993-08-05 Schering Corp Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5.
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
USRE39548E1 (en) * 1994-06-17 2007-04-03 Celltech R&D Limited Interleukin-5 specific recombinant antibodies
US6056957A (en) * 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
US5693323A (en) * 1994-12-23 1997-12-02 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
BR9510499B1 (pt) * 1994-12-23 2009-05-05 antagonistas de il-5 recombinantes úteis no tratamento de distúrbios mediados por il-5.
US5654276A (en) * 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5677280A (en) * 1995-06-07 1997-10-14 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5683983A (en) * 1995-06-07 1997-11-04 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5668110A (en) * 1995-06-07 1997-09-16 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
ATE283926T1 (de) 1995-09-11 2004-12-15 Kyowa Hakko Kogyo Kk Antikörper gegen die alpha-kette von humanem interleukin 5 rezeptor
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
US7109299B1 (en) 1999-12-16 2006-09-19 Affymax, Inc. Peptides and compounds that bind to the IL-5 receptor
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
ATE435239T1 (de) 2002-03-29 2009-07-15 Schering Corp Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
US7927840B2 (en) * 2006-09-11 2011-04-19 Gen Probe Incorporated Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region
AU2003298605B2 (en) * 2002-10-16 2007-10-18 Gen-Probe Incorporated Compositions and methods for detecting west nile virus
ATE471946T1 (de) 2002-12-17 2010-07-15 Merck Patent Gmbh Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
KR101206318B1 (ko) 2004-10-28 2012-11-29 교와 핫꼬 기린 가부시키가이샤 자궁 내막증 치료제
JP5855326B2 (ja) 2005-01-06 2016-02-09 ノヴォ ノルディスク アー／エス 抗ｋｉｒ組み合わせ治療および方法
IL316252A (en) 2005-03-23 2024-12-01 Genmab As Antibodies against cd38 for treatment of multiple myeloma
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
EP2152310A4 (en) 2007-04-30 2010-05-26 Glaxosmithkline Llc METHODS OF ADMINISTERING ANTI-IL-5 ANTIBODIES
AU2009228163B2 (en) 2008-03-28 2012-08-30 Glaxosmithkline Llc Methods of treatment
CA2738001A1 (en) * 2008-10-23 2010-04-29 F. Hoffmann-La Roche Ag Determination of immunoglobulin encoding nucleid acid
US9505826B2 (en) 2010-12-22 2016-11-29 Teva Pharmaceuticals Australia Pty Ltd Modified antibody with improved half-life
EP2791172B1 (en) 2011-12-16 2017-07-19 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
US9677018B2 (en) 2013-01-09 2017-06-13 Thyssenkrupp Industrial Solutions Ag Process for the production of synthesis gas from hard coal
PL3191513T3 (pl) 2014-09-08 2021-02-08 Cephalon, Inc. Zastosowanie reslizumabu do leczenia astmy eozynofilowej od umiarkowanej do ciężkiej
CR20180115A (es) 2015-08-24 2018-04-12 Glaxosmithkline Ip No 2 Ltd Composiciones biofarmacéuticas
CA3064859A1 (en) 2017-06-06 2018-12-13 Glaxosmithkline Llc Biopharmaceutical compositions and methods for pediatric patients
JP2019026625A (ja) * 2017-08-03 2019-02-21 日本全薬工業株式会社 抗イヌｃｄ２０モノクローナル抗体
US11224653B2 (en) 2017-08-24 2022-01-18 Cephalon, Inc. Treatment strategy for non-responders to 100MG subcutaneous mepolizumab
WO2019062831A1 (zh) * 2017-09-29 2019-04-04 江苏恒瑞医药股份有限公司 Il-5抗体、其抗原结合片段及医药用途
CN109942706A (zh) * 2017-12-21 2019-06-28 三生国健药业（上海）股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
ATE98872T1 (de) * 1988-11-03 1994-01-15 Schering Corp Antagonist fuer interleukin-5 zur verhuetung oder verminderung von eosinophilie.
US5096704A (en) 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2041271A1 (en) * 1990-04-30 1991-10-31 Bradford A. Jameson Peptide analogs to proteins of the immunoglobin superfamily
ZA93779B (en) 1992-02-06 1993-08-05 Schering Corp Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5.

Also Published As

Publication number Publication date
SK280610B6 (sk) 2000-05-16
EP0625201A1 (en) 1994-11-23
HU9402293D0 (en) 1994-10-28
AU683836B2 (en) 1997-11-27
FI943635A0 (fi) 1994-08-05
JPH07505767A (ja) 1995-06-29
FI943635A7 (fi) 1994-08-05
KR950700413A (ko) 1995-01-16
NO942912L (no) 1994-10-06
AR248044A1 (es) 1995-05-31
CZ191094A3 (en) 1994-12-15
SG49597A1 (en) 1998-06-15
TNSN93012A1 (fr) 1994-03-17
CA2129445A1 (en) 1993-08-07
ZA93779B (en) 1993-08-05
KR0150060B1 (ko) 1998-08-17
CZ291039B6 (cs) 2002-12-11
FI943635L (fi) 1994-08-05
JP2000210097A (ja) 2000-08-02
NZ249633A (en) 1995-12-21
US6451982B1 (en) 2002-09-17
AU3656093A (en) 1993-09-03
HUT67943A (en) 1995-05-29
SK91894A3 (en) 1995-02-08
RU94045919A (ru) 1996-11-10
NO942912D0 (enExample) 1994-08-05
IL104620A0 (en) 1993-06-10
CN1077991A (zh) 1993-11-03
PL176393B1 (pl) 1999-05-31
WO1993016184A1 (en) 1993-08-19

Similar Documents

Publication Publication Date Title
IL104620A (en) Humanized monoclonal antibodies against human interleukin-5
AU1289795A (en) Monoclonal antibodies specific for human interleukin-5
PL309249A1 (en) Humanised antibodies against l-selectin
HU9601574D0 (en) Humanized antibodies and uses thereof
PL311926A1 (en) Anti-alphav-integrinic monoclonal antibodies
IL108199A0 (en) Monoclonal antibodies against the human il-4 receptor and hybridomas producing the same
EP0823941A4 (en) HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
EP0578515A3 (en) Humanized monoclonal antibodies.
EP0580859A4 (en) Anti-eda monoclonal antibody
GB8910395D0 (en) Human monoclonal antibody and hybridoma producing the same
EP0683675A4 (en) HUMAN MONOCLONAL ANTIBODIES AGAINST CYTOMEGALOVIRUS.
EP0506523A3 (en) Monoclonal antibodies
EP0498767A3 (en) Chimeric antiidiotypic monoclonal antibodies
IL102088A0 (en) Me20:monoclonal antibodies and antigen for human melanoma
EP0508282A3 (en) Anti-idiotypic monoclonal antibodies
ZA951113B (en) Tumor assosiated monoclonal antibody 123av16
HUT65480A (en) Tumor associated monoclonal antibody 88bv59
ZA912136B (en) Anti-oncostatin m monoclonal antibodies
SG64332A1 (en) Monoclonal antibody
GB9212074D0 (en) Monoclonal antibody
AU5852094A (en) Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
IE900593L (en) Monoclonal antibodies
IE901210L (en) Monoclonal antibody
IE900922L (en) Monoclonal antibody
GB9118013D0 (en) Monoclonal antibodies and their use

Legal Events

Date Code Title Description
FF Patent granted
RH1 Patent not in force